New Stock Coverage: Sanchez Energy Set to Make Its Mark

By Justin Sharon  JAN 04, 2013 9:18 AM

Wall Street ratings agencies set the tone for today's stock market.


MINYANVILLE ORIGINAL After two sessions of nonstop gorging, the stock market’s mid-afternoon blood sugar plunge arrived with a vengeance yesterday. Markets were still in positive territory as of 2:00 p.m. Eastern, at which point the Federal Reserve’s December meeting minutes took the punch bowl away and equities eventually ended lower. As winter temperatures plunged to such an extent that even West Texas was snowbound, Nasdaq (^IXIC) — never one to miss out on a party — joined in the frozen funHot Topic (HOTT), up 11.11% to a fresh 52-week peak, was a happy antidote to all the ice. Elsewhere, Internet inventor Al Gore pocketed $100 million from another Al, Jazeera. A perfect day, then, for the arch environmentalist, who simultaneously saw Yingli Green Energy (YGE) surge 16.19%. (Even if, alas, his carbon carping is only so much hot air.) Transocean (RIG) advanced 6.40% after a $1.4 billion settlement from its fiasco in the Gulf of Mexico, where tar still accumulates at our feet several years onFamily Dollar (FDO), from the Tar Heel State of North Carolina, fared far worse, tumbling 12.96% to a 10-month low in posting the S&P 500‘s (^GSPC) poorest performance.

Today in 10:00 a.m. economics, December data for factory orders and the Institute for Supply Management’s non-manufacturing index each are expected to slip slightly from the prior month’s pace. In earnings action, Finish Line (FINL) and Mosaic (MOS) both reported results earlier this morning.
AbbVie (ABBV): Bank of America-Merrill Lynch launches Buy rated research on the drug manufacturer.
Avanir Pharmaceuticals (AVNR): The stock is picked up with an Overweight at Piper Jaffray, which sets it a price objective of $6.
Biotechnology: Robert W. Baird has a new Neutral on Cubist Pharmaceuticals (CBST) ($46 objective), and establishes Outperforms on Achillion Pharmaceuticals (ACHN) ($17), Gilead Sciences (GILD) ($86), and  InterMune (ITMN) ($24.)
Edwards Lifesciences (EW): The equity is launched with a Market Perform at JMP Securities.
FactSet Research Systems (FDS): Goldman Sachs has a fresh Sell, and $79 price target, on FDS.
Humana (HUM): Barclays has an Overweight on the health plan provider.
Natl Oilwell Varco (NOV): NOV is a new Outperform at Macquarie.
Palo Alto Networks (PANW): The tech name, a relatively recent IPO, is picked up with a Buy opinion and $65 target at Topeka.
Sanchez Energy (NYSE:SN): Shares are begun with a Buy at C.K. Cooper, whose target is $25. Catalysts include its oil weighted, Eagle Ford focused development program.
WhiteHorse Finance (WHF): Barclays begins Overweight rated research on the business development outfit.

(See also: Stock Upgrades: No More Tears for Johnson & Johnson and Stock Downgrades: First Solar’s Moment in the Sun Already Over?)
No positions in stocks mentioned.

The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.